P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A. Dimopoulos,Xavier Leleu,Philippe Moreau,Paul G. Richardson,Anna Marina Liberati,Simon J. Harrison,H. Miles Prince,Enrique M. Ocio,Sylvie Assadourian,Frank Campana,Laure Malinge,Dorothée Semiond,Helgi van de Velde,Kwee Yong +13 more
TL;DR: The addition of Isa to Pd improved PFS, ORR and renal response rates, and Isa pharmacokinetics were comparable between the subgroups, suggesting no need for dose adjustment in patients with RI.
Journal ArticleDOI
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
TL;DR: A pivotal, prospective, multinational, phase III trial of DF is underway in patients with severe VOD, and should provide validation of this agent as a therapy for established disease with a high risk of mortality.
Journal ArticleDOI
Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease.
Christopher J. A. Pugh,Victoria S. Sprung,Helen Jones,Paul G. Richardson,Fariba Shojaee-Moradie,A. M. Umpleby,Daniel J. Green,Daniel J. Green,Nigel Timothy Cable,Nigel Timothy Cable,Michael I. Trenell,Graham J. Kemp,Daniel J. Cuthbertson +12 more
TL;DR: At 12 months following cessation of supervision, exercise-mediated improvements in liver fat and other cardiometabolic variables had reversed with cardiorespiratory fitness at baseline levels.
Journal ArticleDOI
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma
Jacob P. Laubach,Javid Moslehi,Sanjeev A. Francis,Jesús F. San Miguel,Pieter Sonneveld,Robert Z. Orlowski,Philippe Moreau,Laura Rosiñol,Edward A. Faber,Peter M. Voorhees,Maria-Victoria Mateos,Loreta Marquez,Huaibao Feng,Avinash Desai,Helgi van de Velde,Jennifer Elliott,Hongliang Shi,Edward Dow,Nishith K. Jobanputra,Dixie Lee Esseltine,Liviu Niculescu,Kenneth C. Anderson,Sagar Lonial,Paul G. Richardson +23 more
TL;DR: Bortezomib‐based treatment was associated with low incidences of cardiac events and Logistic regression analyses of comparative studies showed no impact on cardiac risk with bortezOMib‐ based versus non‐bortzomib-based treatment.
Journal ArticleDOI
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study
Paul G. Richardson,Angela R. Smith,Brandon M. Triplett,Nancy A. Kernan,Stephan A. Grupp,Joseph H. Antin,Leslie Lehmann,Tsiporah B. Shore,Massimo Iacobelli,Maja Miloslavsky,Robin Hume,Alison L. Hannah,Bijan Nejadnik,Robert J. Soiffer +13 more
TL;DR: The potential benefit of defibrotide in treating a VOD/SOS patient population that includes those with and without multiorgan dysfunction is supported, and day +100 survival results observed in this trial were consistent with results seen in previous trials of defIBrotide for VODsOS in adult and pediatric patients.